Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature

Autores
Spaapen, Robbert; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long; Zheng, Yan; Fu, Yang Xin; Luo, Xixi; Cohen, Kenneth S.; Gajewski, Thomas F.
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo.
Fil: Spaapen, Robbert . University Of Chicago; Estados Unidos
Fil: Leung, Michael Y. K.. University Of Chicago; Estados Unidos
Fil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. University Of Chicago; Estados Unidos
Fil: Kline, Justin P.. University Of Chicago; Estados Unidos
Fil: Zhang, Long . University Of Chicago; Estados Unidos
Fil: Zheng, Yan . University Of Chicago; Estados Unidos
Fil: Fu, Yang Xin. University Of Chicago; Estados Unidos
Fil: Luo, Xixi . University Of Chicago; Estados Unidos
Fil: Cohen, Kenneth S. . University Of Chicago; Estados Unidos
Fil: Gajewski, Thomas F. . University Of Chicago; Estados Unidos
Materia
Interferon Beta
Tumor
Vasculature
Therapy
Experimental Melanoma
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/7346

id CONICETDig_bc659ef80c45c83c267c27974ef267d3
oai_identifier_str oai:ri.conicet.gov.ar:11336/7346
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculatureSpaapen, Robbert Leung, Michael Y. K.Fuertes, Mercedes BeatrizKline, Justin P.Zhang, Long Zheng, Yan Fu, Yang XinLuo, Xixi Cohen, Kenneth S. Gajewski, Thomas F. Interferon BetaTumorVasculatureTherapyExperimental Melanomahttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo.Fil: Spaapen, Robbert . University Of Chicago; Estados UnidosFil: Leung, Michael Y. K.. University Of Chicago; Estados UnidosFil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. University Of Chicago; Estados UnidosFil: Kline, Justin P.. University Of Chicago; Estados UnidosFil: Zhang, Long . University Of Chicago; Estados UnidosFil: Zheng, Yan . University Of Chicago; Estados UnidosFil: Fu, Yang Xin. University Of Chicago; Estados UnidosFil: Luo, Xixi . University Of Chicago; Estados UnidosFil: Cohen, Kenneth S. . University Of Chicago; Estados UnidosFil: Gajewski, Thomas F. . University Of Chicago; Estados UnidosAmer Assoc Immunologists2014-10-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/7346Spaapen, Robbert ; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long ; et al.; Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature; Amer Assoc Immunologists; Journal Of Immunology; 193; 8; 15-10-2014; 4254-42600022-17671550-6606enginfo:eu-repo/semantics/altIdentifier/url/http://dx.doi.org/10.4049/jimmunol.1401109info:eu-repo/semantics/altIdentifier/url/http://www.jimmunol.org/content/193/8/4254.longinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:40Zoai:ri.conicet.gov.ar:11336/7346instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:40.599CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
title Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
spellingShingle Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
Spaapen, Robbert
Interferon Beta
Tumor
Vasculature
Therapy
Experimental Melanoma
title_short Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
title_full Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
title_fullStr Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
title_full_unstemmed Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
title_sort Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature
dc.creator.none.fl_str_mv Spaapen, Robbert
Leung, Michael Y. K.
Fuertes, Mercedes Beatriz
Kline, Justin P.
Zhang, Long
Zheng, Yan
Fu, Yang Xin
Luo, Xixi
Cohen, Kenneth S.
Gajewski, Thomas F.
author Spaapen, Robbert
author_facet Spaapen, Robbert
Leung, Michael Y. K.
Fuertes, Mercedes Beatriz
Kline, Justin P.
Zhang, Long
Zheng, Yan
Fu, Yang Xin
Luo, Xixi
Cohen, Kenneth S.
Gajewski, Thomas F.
author_role author
author2 Leung, Michael Y. K.
Fuertes, Mercedes Beatriz
Kline, Justin P.
Zhang, Long
Zheng, Yan
Fu, Yang Xin
Luo, Xixi
Cohen, Kenneth S.
Gajewski, Thomas F.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Interferon Beta
Tumor
Vasculature
Therapy
Experimental Melanoma
topic Interferon Beta
Tumor
Vasculature
Therapy
Experimental Melanoma
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo.
Fil: Spaapen, Robbert . University Of Chicago; Estados Unidos
Fil: Leung, Michael Y. K.. University Of Chicago; Estados Unidos
Fil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental (i); Argentina. University Of Chicago; Estados Unidos
Fil: Kline, Justin P.. University Of Chicago; Estados Unidos
Fil: Zhang, Long . University Of Chicago; Estados Unidos
Fil: Zheng, Yan . University Of Chicago; Estados Unidos
Fil: Fu, Yang Xin. University Of Chicago; Estados Unidos
Fil: Luo, Xixi . University Of Chicago; Estados Unidos
Fil: Cohen, Kenneth S. . University Of Chicago; Estados Unidos
Fil: Gajewski, Thomas F. . University Of Chicago; Estados Unidos
description Endogenous type I IFN production after innate immune recognition of tumor cells is critical for generating natural adaptive immune responses against tumors in vivo. We recently have reported that targeting low doses of IFN-β to the tumor microenvironment using tumor-specific mAbs can facilitate antitumor immunity, which could be augmented further with PD-L1/PD-1 blockade. However, sustained high doses of type I IFNs in the tumor microenvironment, which are potently therapeutic alone, may function through distinct mechanisms. In the current report, we demonstrate that high-dose intratumoral type I IFNs indeed exerted a profound therapeutic effect in the murine B16 model, which unexpectedly did not increase T cell responses. Moreover, bone marrow chimeras revealed a role for type I IFN signaling on nonhematopoietic cells, and most of the therapeutic effect was retained in mice deficient in T, B, and NK cells. Rather, the tumor vasculature was ablated with high-dose intratumoral IFN-β, and conditional deletion of IFN-α/βR in Tie2-positive vascular endothelial cells eliminated most of the antitumor activity. Therefore, the major component of the antitumor activity of sustained high doses of type I IFNs occurs through a direct antiangiogenic effect. Our data help resolve conditions under which distinct antitumor mechanisms of type I IFNs are operational in vivo.
publishDate 2014
dc.date.none.fl_str_mv 2014-10-15
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/7346
Spaapen, Robbert ; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long ; et al.; Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature; Amer Assoc Immunologists; Journal Of Immunology; 193; 8; 15-10-2014; 4254-4260
0022-1767
1550-6606
url http://hdl.handle.net/11336/7346
identifier_str_mv Spaapen, Robbert ; Leung, Michael Y. K.; Fuertes, Mercedes Beatriz; Kline, Justin P.; Zhang, Long ; et al.; Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature; Amer Assoc Immunologists; Journal Of Immunology; 193; 8; 15-10-2014; 4254-4260
0022-1767
1550-6606
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://dx.doi.org/10.4049/jimmunol.1401109
info:eu-repo/semantics/altIdentifier/url/http://www.jimmunol.org/content/193/8/4254.long
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Amer Assoc Immunologists
publisher.none.fl_str_mv Amer Assoc Immunologists
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269299723468800
score 13.13397